Source Articles
Sacituzumab Govitecan
Showing 2 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alati et al. | 2025 | Retrospective | Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION Study | 10.1016/j.ijrobp.2025.11.060 | — | 25 | 55.8 | 7.9 | Breast cancer | any | ADC | Sacituzumab Govitecan | — | Missing | both | Missing | — | 25 | 13 | 42 | 3 | 1 | 5 | 8 | 5 | 21 | RT-related | — | — | 1 | any G3: 1 AE | any G3: 1 pt |
any G3: nausea
|
any G3: nausea
|
| Khatri et al. | 2025 | Retrospective | Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report | 10.1007/s11060-025-05230-7 | — | 26 | 24.0 | 23.4 | Breast cancer | metastatic | ADC | Sacituzumab Govitecan | — | 135 | intra-cranial | brain | — | 24 | 16 | 30 | Missing | 1 | 5 | Missing | 5 | 24 | Radiation necrosis | — | 0 | — | — | — |
—
|
—
|